Publisher
Springer Science and Business Media LLC
Reference10 articles.
1. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–80.e8.
2. Esler M, Esler D. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic. J Hypertens. 2020;38:781–2.
3. Japanese Society of Hypertension. Information of COVID-19. https://www.ipnsh.jp/corona.html. Accessed 7 June 2020.
4. Japanese Circulation Society. Information on COVID-19 in cardiology. https://www.j-circ.or.jp/covid-19/. Accessed 7 June 2020.
5. Kai H, Kai M. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors—lessons from available evidence and insights into COVID-19. Hypertens Res. 2020;43:648–54.